Shamburg News · 8-K filed Oct 19, 2026, 9:15 AM EDT
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter
BCDA · BioCardia, Inc.
- Other event
- Materiality: medium
On October 19, 2026, BioCardia, Inc. announced that the FDA accepted its revised De Novo pre-submission package for marketing clearance of its Helix transendocardial delivery catheter. The company expects FDA substantive review with written feedback and a meeting to discuss approval via the De Novo pathway this quarter. The filing was furnished under Item 8.01 with the press release attached as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001437749-26-032887.
Written from the filing by Shamburg Markets. Figures are as reported by the company.